Assessment of dyspnea in advanced cancer patients

被引:34
|
作者
Mancini, I [1 ]
Body, JJ [1 ]
机构
[1] Inst Jules Bordet, Unite Soins Support & Palliat, B-1000 Brussels, Belgium
基金
英国医学研究理事会;
关键词
dyspnea; assessment tools; palliative care;
D O I
10.1007/s005200050254
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dyspnea, which has been defined as an "umcomfortable awareness of breathing," is a frequent and devastating symptom in advanced cancer patients. It has been reported to occur in 21-79% of patients evaluated a few days or weeks before death. In advanced cancer, the aim of effective management is to minimize the patient's perception of breathlessness, which depends in turn on a reliable assessment. Unfortunately, most of our knowledge and experience of dyspnea has been acquired through working with patients with chronic pulmonary disease, and there is a dearth of literature relating specifically to the assessment of dyspnea in advanced cancer. Dyspnea is a complex sensation including several dimensions, such as antecedents (physiological and psychological events or stimuli preceding the development of dyspnea), mediators (characteristics of individuals or their environment affecting the response), reactions to dyspnea, and consequences or outcomes that result once the individual has reacted to a stimulus. The literature gives us many tools to measure these aspects. For example, antecedents may be assessed by the British Medical Research Council Questionnaire, the American Thoracic Questionnaire (ATS-DLD-78) and the Dyspnea Interview Schedule. Mediators of dyspnea may be measured by the ATS-DLD-78, the Chronic Respiratory Questionnaire (CRQ), the Dyspnea Interview Schedule, the Pulmonary Functional Status Scale (PFSS) and the Therapy Impact Questionnaire (TIQ). Reactions to dyspnea may be assessed by the Dyspnea Visual Analogue Scale (DVAS), the TIQ and the Borg Scale, and the consequences of it by the TIQ, the Baseline Dyspnea Index (BDI), the Transition Dyspnea Index (TDI), and CRQ, and by the Oxygen Cost Diagram (OCD), the Dyspnea Interview Schedule and the Modified Medical Research Council Dyspnea Scale (MRC). No single assessment tool considers all the different components of dyspnea,and the final choice will depend on the purpose of the assessment, taking into account that the provision of quality of life is of paramount importance to patients who have limited time left to them and that the assessment should not therefore detract from the quality of life by being overlong, complicated or invasive.
引用
收藏
页码:229 / 232
页数:4
相关论文
共 50 条
  • [41] Dyspnea during thalidomide treatment for advanced ovarian cancer
    Gordinier, ME
    Dizon, DS
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (05) : 962 - 965
  • [42] Multifactorial Model of Dyspnea in Patients With Cancer
    Shin, Joosun
    Kober, Kord M.
    Yates, Patsy
    Wong, Melisa L.
    Miaskowski, Christine
    ONCOLOGY NURSING FORUM, 2023, 50 (03) : 397 - 415
  • [43] Morphine versus methylprednisolone or aminophylline for relieving dyspnea in patients with advanced cancer in China: a retrospective study
    Tian, Cong
    Wang, Jiong-Yi
    Wang, Mei-Ling
    Jiang, Bin
    Zhang, Lu-Lu
    Liu, Feng
    SPRINGERPLUS, 2016, 5
  • [44] Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer
    Tanaka, K
    Akechi, T
    Okuyama, T
    Nishiwaki, Y
    Uchitomi, Y
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 23 (05) : 417 - 423
  • [45] Prevalence and screening of dyspnea interfering with daily life activities in ambulatory patients with advanced lung cancer
    Tanaka, K
    Akechi, T
    Okuyama, T
    Nishiwaki, Y
    Uchitomi, Y
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 23 (06) : 484 - 489
  • [46] Dyspnea in lung cancer
    Bonnichon, A.
    Le Floch, H.
    Riviere, F.
    Staub, E.
    Mairovitz, A.
    Marotel, C.
    Vaylet, F.
    Margery, J.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2008, 64 (02) : 62 - 68
  • [47] Experience of morphine therapy for refractory dyspnea as palliative care in advanced heart failure patients
    Kawaguchi, Juri
    Hamatani, Yasuhiro
    Hirayama, Atsushi
    Nishimura, Kunihiro
    Nakai, Eri
    Nakamura, Emi
    Miyata, Michi
    Kawano, Yukie
    Takada, Yasuko
    Anchi, Yuta
    Funabashi, Sayaka
    Kuroda, Kensuke
    Azechi, Michiyo
    Takahama, Hiroyuki
    Anzai, Toshihisa
    Yasuda, Satoshi
    Kitaoka, Hiroaki
    Izumi, Chisato
    JOURNAL OF CARDIOLOGY, 2020, 75 (06) : 682 - 688
  • [48] A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients
    Takase, Eri
    Akamatsu, Hiroaki
    Teraoka, Shunsuke
    Nakaguchi, Keita
    Tanaka, Masanori
    Kaki, Takahiro
    Furuta, Katsuyuki
    Sato, Koichi
    Murakami, Eriko
    Sugimoto, Takeya
    Shibaki, Ryota
    Fujimoto, Daichi
    Hayata, Atsushi
    Tokudome, Nahomi
    Ozawa, Yuichi
    Koh, Yasuhiro
    Nakanishi, Masanori
    Kanai, Kuninobu
    Shimokawa, Toshio
    Yamamoto, Nobuyuki
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2024, 67 (03) : 204 - 211.e1
  • [49] The management of dyspnea in cancer patients: a systematic review
    Viola, Raymond
    Kiteley, Cathy
    Lloyd, Nancy S.
    Mackay, Jean A.
    Wilson, Julie
    Wong, Rebecca K. S.
    SUPPORTIVE CARE IN CANCER, 2008, 16 (04) : 329 - 337
  • [50] Opioids for management of episodic breathlessness or dyspnea in patients with advanced disease
    Cabezon-Gutierrez, Luis
    Khosravi-Shahi, Parham
    Custodio-Cabello, Sara
    Muniz-Gonzalez, Francisco
    del Puerto Cano-Aguirre, Maria
    Alonso-Viteri, Soledad
    SUPPORTIVE CARE IN CANCER, 2016, 24 (09) : 4045 - 4055